Patents by Inventor Meiei Cho

Meiei Cho has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220175973
    Abstract: A method for producing a radiopharmaceutical, the method capable of maintaining a radioactive compound retaining a chemical structure and radioactivity at the time of production and after the production, and maintaining a usable period of a radiopharmaceutical; and a radiopharmaceutical are provided. The method for producing a radiopharmaceutical that has a radioactive component containing a radioactive dithiosemicarbazone copper complex includes: a stabilization step of adding a stabilizing agent containing at least one compound selected from the group consisting of ascorbic acid, methionine, sodium ascorbate, mannitol, and butylhydroxyanisole to a solution containing the radioactive component; and a filtration step of filtering the solution containing the radioactive component or a precursor thereof with a sterilization filter. In the radiopharmaceutical, a concentration of the radioactive component is 200 MBq/mL or more in terms of radioactivity concentrations.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 9, 2022
    Inventors: Yukie Yoshii, Meiei Cho, Kazunori Kawamura, Hisashi Suzuki, Hiroki Hashimoto
  • Publication number: 20220133698
    Abstract: The present invention provides an ?-synuclein aggregate binding agent that has high binding selectivity for an ?-synuclein aggregate. The ?-synuclein aggregate binding agent contains a compound represented by a formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: in the formula (I), R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; the ring A is a benzene or pyridine ring; the ring B is represented by the following formula (i) or (ii): R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 5, 2022
    Inventors: Makoto Higuchi, Maiko Ono, Tetsuya Suhara, Meiei Cho
  • Publication number: 20220056020
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Application
    Filed: September 16, 2021
    Publication date: February 24, 2022
    Inventors: Makoto HIGUCHI, Tetsuya SUHARA, Masahiro MARUYAMA, Meiei CHO, Hitoshi SHIMADA
  • Publication number: 20200262829
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and [Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 20, 2020
    Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
  • Patent number: 10604516
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 31, 2020
    Assignee: National Institutes for Quantum and Radiological Science and Technology
    Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
  • Patent number: 10335503
    Abstract: The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO2; each of X and Y independently represents S or O; each of R1-R4 independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each R5 independently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: July 2, 2019
    Assignee: Public University Corporation Yokohama City University
    Inventors: Takuya Takahashi, Tomoyuki Miyazaki, Tetsuya Suhara, Makoto Higuchi, Meiei Cho
  • Publication number: 20180200391
    Abstract: The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO2; each of X and Y independently represents S or O; each of R1-R4 independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each R5 independently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.
    Type: Application
    Filed: July 5, 2016
    Publication date: July 19, 2018
    Applicant: Public University Corporation Yokohama City University
    Inventors: Takuya Takahashi, Tomoyuki Miyazaki, Tetsuya Suhara, Makoto Higuchi, Meiei Cho
  • Publication number: 20160045625
    Abstract: A compound selected from the group consisting of compounds represented by the formulas below or pharmaceutically acceptable salt thereof is useful in PET imaging for AMPA receptor.
    Type: Application
    Filed: April 2, 2014
    Publication date: February 18, 2016
    Inventors: Norihito Oi, Noboru Yamamoto, Michiyuki Suzuki, Yosuke Nakatani, Tetsuya Suhara, Meiei Cho, Toshimitsu Fukumura, Makoto Higuchi, Takafumi Minamimoto, Jun Maeda, Masaki Tokunaga, Yuji Nagai
  • Publication number: 20150239878
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Application
    Filed: December 21, 2012
    Publication date: August 27, 2015
    Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada